N.M. Vageesh*, M. Misbahuddin, P. Suresh
Dept. of Pharmaceutics, St. Johns College of Pharmaceutical Sciences, Yerrakota, Yemmiganur, Kurnool (Dist), A.P.
A B S T R A C T
In present study transdermal drug delivery of Lisuride was developed to overcome the first pass metabolism and to reduce frequency of dosing compared to oral route. Oral drug delivery system has various drawbacks like poor bioavailability due to hepatic metabolism (first pass) and the tendency to produce rapid blood level spikes (both high and low), leading to a need for high and/or frequent dosing, which can be both cost prohibitive and inconvenient. Matrix type of transdermal patches was developed by using polymers Eudragit polymers Transdermal patches were prepared by employing solvent casting method. Drug excipient compatibility studies were carried out by using FTIR, and it was observed that there were no interactions. Formulations were prepared with the varying concentrations polymers ranging from F1-F9, and all the formulations were evaluated for various physical parameters Physical appearance, Flatness, Weight variation, Thickness, Folding endurance, Drug content, Moisture uptake, Moisture content and Swelling study and all the results were found to be were found to be within the pharmacopeial limits, in-vitro drug release studies by using dialysis membrane. Among all the 12 formulations F9 formulation which contains Eudragit S-100 and Eudragit L-100 25mg each had shown 99.6% cumulative drug release within 8 hours.
Keywords: Lisuride, Transdermal patches, Eudragit S-100, Eudragit L-100